Partners
Sponsors
Ambassadors
Health & Wellness Partners
Fertility Partner
Randox Health - Testing Partner

Polycystic Ovary Syndrome (PCOS) is a common hormonal disorder that affects women of reproductive age. It is characterized by high levels of androgens (male hormones) in the body, which can cause irregular periods, acne, excessive hair growth, and weight gain. PCOS can also increase the risk of developing other health conditions such as diabetes, heart disease, and infertility.
While there is no cure for PCOS, lifestyle changes such as diet and exercise can help manage its symptoms and reduce the risk of associated health problems. At PCOS Relief, we offer diet and nutrition classes in the UK to help women with PCOS make informed choices about their diet and improve their overall health.
Our classes are designed by nutritionists and dietitians who specialize in PCOS management. They are tailored to meet the specific needs of women with PCOS, taking into account their unique hormonal imbalances, metabolic challenges, and dietary preferences. Our classes cover a wide range of topics related to PCOS and nutrition, including:
Our classes are available in-person and online, and are open to women of all ages and backgrounds. We also offer weight loss courses in the UK for women with PCOS who need extra support in managing their weight. Our weight loss courses are designed by qualified personal trainers who specialize in PCOS management, and are tailored to meet the specific needs of each participant. They include:
Published in The Lancet, May 2026 · Endorsed by the Endocrine Society · 56 global organisations
What was PCOS?
A hormonal condition named after the appearance of follicles on the ovaries — a term widely recognised as inaccurate, leading to delayed diagnoses and misunderstood care for millions.
What is PMOS?
A complex, long-term condition involving multiple hormone imbalances, metabolic effects like insulin resistance, and impacts on reproductive, mental, and cardiovascular health — far beyond just the ovaries.
After a decade-long global study with 22,000+ patients and clinicians, the new name was published in The Lancet to reduce diagnostic delays affecting up to 70% of women living with this condition.